{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05410145","nct_id":"NCT05410145","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05410145. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Part 1: Dose Escalation, D3S-001 administered orally.\n\nPart 2 and Part 3a Arm C: Dose Expansion, D3S-001 administered orally in selected cancer type patients.\n\nPart 4a: Dose Optimization, D3S-001 administered orally in selected cancer type patients.","label":"D3S-001 monotherapy","type":"EXPERIMENTAL"},{"description":"Part 3a Arm A: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nPembrolizumab administered intravenously.","label":"D3S-001 and pembrolizumab","type":"EXPERIMENTAL"},{"description":"Part 3a Arm B: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nCisplatin + pemetrexed administered intravenously\n\nor\n\nCarboplatin + pemetrexed administered intravenously","label":"D3S-001 and platinum doublet chemotherapy (cisplatin + pemetrexed or carboplatin + pemetrexed)","type":"EXPERIMENTAL"},{"description":"Part 3b: Dose Expansion, D3S-001 in combination therapy administered orally in selected cancer type patients.\n\nCetuximab administered intravenously.","label":"D3S-001 and Cetuximab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-04","type":"ESTIMATED"},"conditions":["KRAS P.G12C"],"enrollment":{"count":442,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"D3S-001","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"},{"name":"Cetuximab","type":"DRUG"}],"last_update":"2026-09-15","lead_sponsor":"D3 Bio (Wuxi) Co., Ltd","official_title":"A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"From first dose until 30 days after the last dose (or specified in the protocol)."},{"measure":"Number of Participants With Dose-Limiting Toxicities (DLTs)","timeFrame":"From Cycle 1 Day 1 through Day 21. Each cycle is 21 days."}],"references":[{"citation":"Cho BC, Lu S, Lee MA, Song Z, Park JJ, Lim SM, Li Z, Zhao J, Richardson G, Zhang Y, Zhang J, Liu A, Loong HH, Chen C, Wang J, Shen Y, Fan Z, Chen Q, Wang H, Zhang J, Chen ZJ, Johnson ML, Mok T. D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial. Nat Med. 2025 Aug;31(8):2768-2777. doi: 10.1038/s41591-025-03688-6. Epub 2025 Apr 29.","pmid":"40301557","type":"DERIVED"}],"start_date":{"date":"2022-08-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","url":"https://clinicaltrials.gov/study/NCT05410145"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05410145"}